Lilly sues six sellers over black-market retatrutide, including peptide vendors
Defendants include compounding pharmacies, a med spa and online peptide sellers marketing the unapproved triple agonist still in Phase 3 trials.
DO
By Daniel Okafor · Regulatory Correspondent
Aug 12 03:00 ETSource: CNBC
The wire
- 01Eli Lilly filed six lawsuits against Aesthetic Envy Cosmetic Centers, Astra, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide over alleged illegal sales of retatrutide.
- 02The FDA said in June that retatrutide and other unapproved GLP-1 products cannot lawfully be compounded or sold to consumers, putting gray-market sellers on direct legal footing.
- 03Lilly says it has referred more than 200 individuals and entities to FDA, DOJ, state attorneys general and licensing boards; Customs intercepted over 1,400 illicit GLP-1 shipments in July alone.
From the source
Read at cnbc.comLilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide
Eli Lilly on Wednesday said it had filed six lawsuits against U.S. companies it accuses of illegally selling black-market versions of its experimental obesity drug retatrutide, escalating its campaign against unauthorized sellers before the medicine has won regulatory approval.